MedTrace Logo

Drug-Drug Interaction Study to Evaluate the Effect of DWC202511 or DWC202512 With DWP16001 in Healthy Adults

NCT07213310 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2026-02-11

No results posted yet for this study

Summary

Drug-Drug Interaction Study to Evaluate the Effect of DWC202511 or DWC202512 With DWP16001 in Healthy Adults

Conditions

  • Healthy

Interventions

DRUG

DWP16001

DWP16001 enavogliflozin (single oral dose) is administered in accordance with the study protocol.

DRUG

DWC202511

Repeated oral administration of DWC202511 500 mg twice daily (BID), in accordance with the study protocol.

DRUG

DWC202512

Repeated oral administration of DWC202512 once daily, in accordance with the study protocol

Sponsors & Collaborators

  • Daewoong Pharmaceutical Co. LTD.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-11-09
Primary Completion
2026-01-07
Completion
2026-01-07

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07213310 on ClinicalTrials.gov